Canopy Growth (CGC) Total Non-Current Liabilities (2017 - 2026)
Canopy Growth (CGC) reported Total Non-Current Liabilities of $279.8 million for Q1 2026, little changed on a YoY basis from $280.8 million in Q1 2025, and up 12.13% sequentially from $249.6 million in Q4 2025.
Canopy Growth (CGC) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Canopy Growth (CGC) has 10 years of Total Non-Current Liabilities data on file, last reported at $279.8 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities changed 0.33% year-over-year to $279.8 million; the trailing twelve-month figure through Mar 2026 stood at $279.8 million (changed 0.33% YoY), and the FY2026 full-year result was $279.8 million, changed 0.33% from the prior year.
- Total Non-Current Liabilities climbed to $279.8 million in Q1 2026, from $249.6 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.5 billion in Q1 2022 to a low of $242.6 million in Q3 2025.
- A 5-year average of $726.7 million and a median of $598.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities tumbled 54.31% in 2025 and fell 0.33% in 2026, its largest moves.
- Tracing CGC's Total Non-Current Liabilities over 5 years: stood at $1.1 billion in 2022, then plunged by 47.26% to $598.7 million in 2023, then slumped by 31.52% to $410.0 million in 2024, then sank by 39.13% to $249.6 million in 2025, then advanced by 12.13% to $279.8 million in 2026.
- Business Quant data shows CGC's Total Non-Current Liabilities at $279.8 million in Q1 2026, $249.6 million in Q4 2025, and $242.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - | 279.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 279.84 Mn |
| Dec 31, 2025 | 249.56 Mn |
| Sep 30, 2025 | 242.57 Mn |
| Jun 30, 2025 | 300.01 Mn |
| Mar 31, 2025 | 280.76 Mn |
| Dec 31, 2024 | 410.00 Mn |
| Sep 30, 2024 | 529.76 Mn |
| Jun 30, 2024 | 550.77 Mn |
| Mar 31, 2024 | 614.43 Mn |
| Dec 31, 2023 | 598.71 Mn |
| Sep 30, 2023 | 685.33 Mn |
| Jun 30, 2023 | 926.46 Mn |
| Mar 31, 2023 | 1.24 Bn |
| Dec 31, 2022 | 1.14 Bn |
| Sep 30, 2022 | 1.34 Bn |
| Jun 30, 2022 | 1.42 Bn |
| Mar 31, 2022 | 1.55 Bn |
| Dec 31, 2021 | 1.51 Bn |
| Sep 30, 2021 | 1.64 Bn |
| Jun 30, 2021 | 2.10 Bn |